Skip to main content
Top
Published in: CNS Drugs 8/2019

01-08-2019 | Antiepileptic Drugs | Systematic Review

Intravenous Brivaracetam in the Treatment of Status Epilepticus: A Systematic Review

Authors: Francesco Brigo, Simona Lattanzi, Raffaele Nardone, Eugen Trinka

Published in: CNS Drugs | Issue 8/2019

Login to get access

Abstract

Background

Brivaracetam is a high-affinity synaptic vesicle glycoprotein 2A ligand with high brain permeability and rapid onset of action. These properties make brivaracetam potentially an ideal compound in the emergency setting.

Objective

The objective of our study was to review the evidence about the clinical efficacy and tolerability of intravenous brivaracetam in the treatment of status epilepticus.

Methods

We systematically searched MEDLINE, EMBASE, Google Scholar, ClinicalTrials.gov, and conference proceedings to identify studies evaluating intravenous brivaracetam as treatment for status epilepticus of any type in patients of any age. Searches were conducted on 3 December, 2018.

Results

Seven studies were included (37 patients; aged 22–85 years; 21 were female). The type and etiology of status epilepticus varied across studies. The number of drugs used prior to brivaracetam to treat status epilepticus ranged from 1 to 8. The time from status epilepticus onset to brivaracetam administration ranged from 0.5 h to 105 days. The initial brivaracetam dose ranged from 50 to 400 mg. In case series, the proportion of patients achieving clinical status epilepticus cessation when brivaracetam was administered as the last drug varied from 27 to 50%; in case reports, all patients had status epilepticus cessation. The time from brivaracetam administration to status epilepticus cessation ranged from 15 min to 94 h. No serious adverse effects were reported.

Conclusions

The available data suggested that brivaracetam can be a safe treatment option in patients with status epilepticus. The current evidence is however hampered by several confounding factors, and controlled studies are warranted to define the actual benefit of brivaracetam for the treatment of status epilepticus.
Literature
1.
go back to reference Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus: report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56:1515–23.CrossRefPubMed Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus: report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56:1515–23.CrossRefPubMed
2.
go back to reference Logroscino G, Hesdorffer DC, Cascino G, et al. Mortality after a first episode of status epilepticus in the United States and Europe. Epilepsia. 2005;46(Suppl. 11):46–8.CrossRefPubMed Logroscino G, Hesdorffer DC, Cascino G, et al. Mortality after a first episode of status epilepticus in the United States and Europe. Epilepsia. 2005;46(Suppl. 11):46–8.CrossRefPubMed
3.
go back to reference Leitinger M, Trinka E, Giovannini G, et al. Epidemiology of status epilepticus in adults: a population-based study on incidence, causes, and outcomes. Epilepsia. 2019;60:53–62.CrossRefPubMed Leitinger M, Trinka E, Giovannini G, et al. Epidemiology of status epilepticus in adults: a population-based study on incidence, causes, and outcomes. Epilepsia. 2019;60:53–62.CrossRefPubMed
5.
go back to reference Trinka E, Höfler J, Leitinger M, et al. Pharmacologic treatment of status epilepticus. Expert Opin Pharmacother. 2016;17:513–34.CrossRefPubMed Trinka E, Höfler J, Leitinger M, et al. Pharmacologic treatment of status epilepticus. Expert Opin Pharmacother. 2016;17:513–34.CrossRefPubMed
6.
go back to reference Brigo F, Bragazzi NL, Bacigaluppi S, et al. Is intravenous lorazepam really more effective and safe than intravenous diazepam as first-line treatment for convulsive status epilepticus? A systematic review with meta-analysis of randomized controlled trials. Epilepsy Behav. 2016;64:29–36.CrossRefPubMed Brigo F, Bragazzi NL, Bacigaluppi S, et al. Is intravenous lorazepam really more effective and safe than intravenous diazepam as first-line treatment for convulsive status epilepticus? A systematic review with meta-analysis of randomized controlled trials. Epilepsy Behav. 2016;64:29–36.CrossRefPubMed
7.
go back to reference Brigo F, Bragazzi NL, Lattanzi S, et al. A critical appraisal of randomized controlled trials on intravenous phenytoin in convulsive status epilepticus. Eur J Neurol. 2018;25:451–63.CrossRefPubMed Brigo F, Bragazzi NL, Lattanzi S, et al. A critical appraisal of randomized controlled trials on intravenous phenytoin in convulsive status epilepticus. Eur J Neurol. 2018;25:451–63.CrossRefPubMed
9.
go back to reference Rolan P, Sargentini-Maier ML, Pigeolet E, et al. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. Br J Clin Pharmacol. 2008;66:71–5.CrossRefPubMedPubMedCentral Rolan P, Sargentini-Maier ML, Pigeolet E, et al. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. Br J Clin Pharmacol. 2008;66:71–5.CrossRefPubMedPubMedCentral
10.
go back to reference Sargentini-Maier ML, Espie P, Coquette A, et al. Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos. 2008;36:36–45.CrossRefPubMed Sargentini-Maier ML, Espie P, Coquette A, et al. Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos. 2008;36:36–45.CrossRefPubMed
11.
go back to reference Strzelczyk A, Klein KM, Willems LM, et al. Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus. Expert Rev Clin Pharmacol. 2016;9:637–45.CrossRefPubMed Strzelczyk A, Klein KM, Willems LM, et al. Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus. Expert Rev Clin Pharmacol. 2016;9:637–45.CrossRefPubMed
12.
go back to reference Nicolas JM, Hannestad J, Holden D, et al. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia. 2016;57:201–9.CrossRefPubMed Nicolas JM, Hannestad J, Holden D, et al. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia. 2016;57:201–9.CrossRefPubMed
13.
go back to reference Finnema SJ, Rossano S, Naganawa M, et al. A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers. Epilepsia. 2019;60:958–67.PubMedPubMedCentral Finnema SJ, Rossano S, Naganawa M, et al. A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers. Epilepsia. 2019;60:958–67.PubMedPubMedCentral
14.
go back to reference Wasterlain CG, Suchomelova L, Matagne A, et al. Brivaracetam is a potent anticonvulsant in experimental status epilepticus. Epilepsia. 2005;46(Suppl. 8):219. Wasterlain CG, Suchomelova L, Matagne A, et al. Brivaracetam is a potent anticonvulsant in experimental status epilepticus. Epilepsia. 2005;46(Suppl. 8):219.
15.
go back to reference Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777–84.CrossRefPubMed Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777–84.CrossRefPubMed
16.
go back to reference Beier CP, Blaabjerg M. Successful treatment of status epilepticus with brivaracetam. In: American Epilepsy Society Annual Meeting; 2–6 Dec, 2016; Houston (TX): abstract no. 1.193. Beier CP, Blaabjerg M. Successful treatment of status epilepticus with brivaracetam. In: American Epilepsy Society Annual Meeting; 2–6 Dec, 2016; Houston (TX): abstract no. 1.193.
17.
go back to reference Fleming D, Clayton SM, Ray B. Posterior reversible encephalopathy syndrome and refractory status epilepticus treated with ketamine and brivaracetam. Neurocrit Care. 2017;27(Suppl. 1):S448. Fleming D, Clayton SM, Ray B. Posterior reversible encephalopathy syndrome and refractory status epilepticus treated with ketamine and brivaracetam. Neurocrit Care. 2017;27(Suppl. 1):S448.
18.
go back to reference Strzelczyk A, Steinig I, Willems LM, et al. Treatment of refractory and super-refractory status epilepticus with brivaracetam: a cohort study from two German university hospitals. Epilepsy Behav. 2017;70:177–81.CrossRefPubMed Strzelczyk A, Steinig I, Willems LM, et al. Treatment of refractory and super-refractory status epilepticus with brivaracetam: a cohort study from two German university hospitals. Epilepsy Behav. 2017;70:177–81.CrossRefPubMed
19.
go back to reference Strzelczyk A, Kay L, Bauer S, et al. Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus. Epilepsia. 2018;59:1549–56.CrossRefPubMed Strzelczyk A, Kay L, Bauer S, et al. Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus. Epilepsia. 2018;59:1549–56.CrossRefPubMed
20.
go back to reference Manacheril R, Khan FA, Steven A, et al. Focal status epilepticus in a patient with stroke like migraine attacks after radiation therapy (SMART) syndrome. Clin Neurophysiol. 2018;129(Suppl. 1):e74.CrossRef Manacheril R, Khan FA, Steven A, et al. Focal status epilepticus in a patient with stroke like migraine attacks after radiation therapy (SMART) syndrome. Clin Neurophysiol. 2018;129(Suppl. 1):e74.CrossRef
21.
go back to reference Kalss G, Rohracher A, Leitinger M, et al. Intravenous brivaracetam in status epilepticus: a retrospective single-center study. Epilepsia. 2018;59(Suppl. 2):228–33.CrossRefPubMed Kalss G, Rohracher A, Leitinger M, et al. Intravenous brivaracetam in status epilepticus: a retrospective single-center study. Epilepsia. 2018;59(Suppl. 2):228–33.CrossRefPubMed
22.
go back to reference Aicua-Rapun I, André P, Rossetti AO, et al. Intravenous brivaracetam in status epilepticus: correlation between loading dose, plasma levels and clinical response. Epilepsy Res. 2019;149:88–91.CrossRefPubMed Aicua-Rapun I, André P, Rossetti AO, et al. Intravenous brivaracetam in status epilepticus: correlation between loading dose, plasma levels and clinical response. Epilepsy Res. 2019;149:88–91.CrossRefPubMed
24.
go back to reference Rossetti AO, Alvarez V, Januel JM, Burnand B. Treatment deviating from guidelines does not influence status epilepticus prognosis. J Neurol. 2013;260:421–8.CrossRefPubMed Rossetti AO, Alvarez V, Januel JM, Burnand B. Treatment deviating from guidelines does not influence status epilepticus prognosis. J Neurol. 2013;260:421–8.CrossRefPubMed
25.
go back to reference Perrenoud M, André P, Alvarez V, et al. Intravenous lacosamide in status epilepticus: correlation between loading dose, serum levels, and clinical response. Epilepsy Res. 2017;135:38–42.CrossRefPubMed Perrenoud M, André P, Alvarez V, et al. Intravenous lacosamide in status epilepticus: correlation between loading dose, serum levels, and clinical response. Epilepsy Res. 2017;135:38–42.CrossRefPubMed
26.
go back to reference Paulson OB, Gyory A, Hertz MM. Blood–brain barrier transfer and cerebral uptake of antiepileptic drugs. Clin Pharmacol Ther. 1982;32:466–77.CrossRefPubMed Paulson OB, Gyory A, Hertz MM. Blood–brain barrier transfer and cerebral uptake of antiepileptic drugs. Clin Pharmacol Ther. 1982;32:466–77.CrossRefPubMed
27.
go back to reference Niquet J, Suchomelova L, Thompson K, et al. Acute and long-term effects of brivaracetam and brivaracetam-diazepam combinations in an experimental model of status epilepticus. Epilepsia. 2017;58:1199–207.CrossRefPubMedPubMedCentral Niquet J, Suchomelova L, Thompson K, et al. Acute and long-term effects of brivaracetam and brivaracetam-diazepam combinations in an experimental model of status epilepticus. Epilepsia. 2017;58:1199–207.CrossRefPubMedPubMedCentral
28.
go back to reference Brigo F, Bragazzi N, Nardone R, Trinka E. Direct and indirect comparison meta-analysis of levetiracetam versus phenytoin or valproate for convulsive status epilepticus. Epilepsy Behav. 2016;64:110–5.CrossRefPubMed Brigo F, Bragazzi N, Nardone R, Trinka E. Direct and indirect comparison meta-analysis of levetiracetam versus phenytoin or valproate for convulsive status epilepticus. Epilepsy Behav. 2016;64:110–5.CrossRefPubMed
29.
go back to reference Navarro V, Dagron C, Elie C, SAMUKeppra Investigators, et al. Prehospital treatment with levetiracetam plus clonazepam or placebo plus clonazepam in status epilepticus (SAMUKeppra): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2016;15:47–55.CrossRefPubMed Navarro V, Dagron C, Elie C, SAMUKeppra Investigators, et al. Prehospital treatment with levetiracetam plus clonazepam or placebo plus clonazepam in status epilepticus (SAMUKeppra): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2016;15:47–55.CrossRefPubMed
31.
go back to reference Kellinghaus C, Rossetti AO, Trinka E, et al. SENSE registry for status epilepticus. Epilepsia. 2018;59:150–4.CrossRefPubMed Kellinghaus C, Rossetti AO, Trinka E, et al. SENSE registry for status epilepticus. Epilepsia. 2018;59:150–4.CrossRefPubMed
Metadata
Title
Intravenous Brivaracetam in the Treatment of Status Epilepticus: A Systematic Review
Authors
Francesco Brigo
Simona Lattanzi
Raffaele Nardone
Eugen Trinka
Publication date
01-08-2019
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 8/2019
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.1007/s40263-019-00652-0

Other articles of this Issue 8/2019

CNS Drugs 8/2019 Go to the issue